Predict your next investment

Corporation
HEALTHCARE | Biotechnology
olixpharma.com

See what CB Insights has to offer

Founded Year

2010

Stage

IPO | IPO

Date of IPO

7/18/2018

Market Cap

591.29B

About OliX Pharmaceuticals

OliX Pharmaceuticals (KOSDAQ: 226950) is a biotechnology and pharmaceutical company. The company develops ribonucleic acid interference technology, ribonucleic acid interference therapeutics, and pharmaceuticals for the treatment of macular degeneration. It is based in Suwon-si, South Korea.

OliX Pharmaceuticals Headquarter Location

Ace Gwanggyo Tower 1 No. 1014 17 Daehak4-ro, Yeongtong-gu

Suwon-si, 16226,

South Korea

Latest OliX Pharmaceuticals News

OliX Pharmaceuticals Enters Agreement With Pharmaron To Advance Non-clinical Toxicology Testing For Hepatitis B Candidate OLX703A

Oct 20, 2021

Oct 20, 2021 8:30 AM EDT OliX Pharmaceuticals Enters Agreement With Pharmaron To Advance Non-clinical Toxicology Testing For Hepatitis B Candidate OLX703A Previous non-clinical pharmacology study demonstrated substantial reduction in serum markers of HBV Author: SUWON, Republic of Korea, Oct. 20, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has selected Pharmaron, a leading contract research organization based in China, to conduct non-clinical toxicity studies to evaluate the safety of OLX703A, OliX's investigational therapeutic for hepatitis B (HBV). OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg). It allows suppression of HBV replication and has been confirmed to be functional against all major HBV genotypes and subtypes. Last June, OliX conducted a non-clinical pharmacology study of OLX703A and observed an approximately 100-fold reduction of key markers in serum associated with HBV, including s-antigen, e-antigen, and HBV DNA. According to the Company, these key results are comparable to the published preclinical data of competing therapeutics. Active pharmaceutical ingredient (API) production of OLX703A for preclinical and clinical studies is currently underway with LGC BioSearch Technologies. "We are pleased to work with Pharmaron to advance non-clinical toxicity studies for OLX703A given their extensive research and development experience in China and the broader Asia region," said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals. "We are encouraged by our progress in developing therapeutics for liver disease based on our GalNAc-asiRNA technology and look forward to advancing OLX703A into clinical trials as quickly as possible." About OliX Pharmaceuticals OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes based on its own proprietary RNAi technology. The Company's core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

OliX Pharmaceuticals Patents

OliX Pharmaceuticals has filed 18 patents.

The 3 most popular patent topics include:

  • RNA
  • Molecular biology
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/21/2018

9/14/2021

Androgens and anabolic steroids, Androstanes, Antiandrogens, Prodrugs, Hepatotoxins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/21/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/14/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Androgens and anabolic steroids, Androstanes, Antiandrogens, Prodrugs, Hepatotoxins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

OliX Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OliX Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.